Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

First Partnership in India and New Product Launch

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets neuroscience technology to assess brain health, announces a partnership with a major pharmaceutical company to deliver online neurological testing to patients in India using the Company's cloud-based CANTAB Connect platform.

The contract includes an upfront payment of over £200,000 for the adaptation of an existing CANTAB digital cognitive health product for use by clinicians in the Indian healthcare market. As part of the product's development a normative data study will be conducted with 1,500 Indian participants aged 10 - 90 years old before being validated in a clinical study with a further 1,500 patients - both studies being funded by the pharmaceutical partner.

Once validated, the sponsor will market the software to clinicians throughout India and pay an annual licence fee to Cambridge Cognition for use of the product plus additional annual fees per clinical user.

The need for a standardised, online screening assessment, such as CANTAB, which can be used by general practitioners, is believed to be important in combating the burden of neurological diseases in India.

Over 30 million people currently suffer from neurological disease in India creating a growing health crisis1. The problem is compounded by a paucity of trained medical experts, with only one neurologist per 1,250,000 population2. The result is patients being seen by general practitioners with limited knowledge about neurology, leading to low rates of diagnosis and poor treatment of disorders.

The new product being developed by Cambridge Cognition will enable general practitioners to consistently conduct expert neuropsychological assessments in 20 minutes without the need for formal training. Using gold standard CANTAB cognitive tests, the software, which is already in use in the UK NHS, will help to identify early signs of neuropsychological impairment, support timely diagnoses and provide instant feedback to patients at scale.

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition said: "This is the first time an effort has been made, on this scale, to provide Indian physicians with a sensitive, objective and user friendly digital cognitive screening tool. This will have significant impact on the ability to detect and treat neurological conditions in India with long term clinical benefits and substantial commercial potential."

References

1 Gourie-Devi M (2016). Epidemiology of neurological disorders in India. Neurology India. 2016 Sep-Oct;64(5):1110-1. doi: 10.4103/0028-3886.190298.

2 Gourie-Devi M (2008). Organization of neurology services in India: Unmet needs and the way forward. Neurology India 2008; 56:4-12

Enquiries

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com